WHO issues global guideline on the use of GLP-1 medicines in treating obesity
WHO3 days
Weight loss drugs target symptoms rather than root causes and fail to deliver sustainable results beyond two years. These medications carry serious risks from heart valve damage to suicide while costing enormous sums, yet they cannot compensate for the fundamental mismatch between modern lifestyles and human metabolism shaped by millennia of scarcity.
GLP-1 therapies represent a breakthrough in treating obesity as the chronic disease it is, offering proven benefits for cardiovascular health, diabetes prevention and kidney function. With 3.7 million obesity-related deaths in 2024 and costs reaching $3 trillion annually by 2030, these medications provide essential tools within comprehensive care that combines behavioral support and medical treatment.
© 2025 Improve the News Foundation.
All rights reserved.
Version 6.18.0